HPTN
Dec 10, 2020 | In the Media, News
Wafaa El-Sadr, MD, MPH, MPA, global director of ICAP, was noted in a Dec 7 article in POZ magazine which discussed how the national system of HIV clinical trials has been reorganized and refined. Specifically, the new structure divides trials into four distinct...
Dec 3, 2020 | In the Media, News
Wafaa El-Sadr, MD, MPH, MPA, global director of ICAP, was featured in a Nov 30 article by Global News Wire which announced that ICAP has been awarded a seven-year grant from the U.S. National Institutes of Health as part of the next funding cycle (2020-2027) for the...
Jul 7, 2020 | News
Researchers from the HIV Prevention Trials Network (HPTN) announced today that the HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every eight weeks was superior to daily oral...
May 19, 2020 | In the Media, News
The HIV Prevention Trials Network (HPTN) announced results from HPTN 083, a global randomized, controlled, double-blind study that compared the safety and efficacy of long-acting injectable cabotegravir (CAB LA) to daily oral tenofovir/emtricitabine (TDF/FTC)...
Jul 22, 2019 | In the Media, News
HPTN 071 (PopART) examined the impact of a package of HIV prevention interventions, including universal testing and treatment, on community-level HIV incidence amongst more than one million people living in 21 urban and peri-urban communities in Zambia and South...
